Shares of Tonix Pharmaceuticals Holding, Corp. (NASDAQ:TNXP) Rocket as its Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation

Shares of Tonix Pharmaceuticals Holding, Corp. (NASDAQ:TNXP) Rocket as its Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation

Developer of next-generation medicines for common disorders of the central nervous system, with its lead program focusing on posttraumatic stress disorder, Tonix Pharmaceuticals Holding, Corp. (NASDAQ:TNXP), announces that the FDA has granted a breakthrough therapy designation for TNX-102 SL. NEW YORK, Dec. 19, 2016 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that the U.S. Food and Drug Administration […]

Read More ˃